INmune Bio Reports Positive Results From Early-Stage Trial Of Alzheimer's Treatment; Shares Jump 14%

(RTTNews) - Shares of INmune Bio, Inc. (INMB) jumped nearly 14% in extended trading session on Wednesday after the company reported positive results from an early stage study of its treatment for Alzheimer's disease.

The company reported that its XPro treatment showed statistically significant decrease in Phospho Tau 217 (pT271) and pT181, a type of protein associated with the disease and other neurological diseases, and an improvement in an imaging biomarker of myelination.

Alzheimer's patients treated with 1.0 mg/kg of XPro once a week for three months had a 46% reduction is CSF pT217 and a lesser reduction in pT181.

"CSF pT217 appears to be the more sensitive tau biomarker of neurodegeneration in patients with AD, and our data show that controlling neuroinflammation decreases pT217," said CJ Barnum, PhD, Head of Neurosciences for INmune Bio. "Tau pathology has been associated with decreased white matter integrity in AD and we believe these data are consistent with our biomarkers for the measurement of white matter pathology in patients with AD. White matter pathology starts early, the changes are measurable, and appear to be reversed following treatment with XProTM."

INMB closed Wednesday's trading at $23.87, up $0.15 or 0.63%, on the Nasdaq. The stock further gained $3.24 or 13.57% in the after-hours trading.